source
- Boehringer targets 2027 submission of obesity drug survodutide after positive cardiovascular trialBoehringer Ingelheim announced that its experimental obesity therapy survodutide is moving toward regulatory filing. The move follows the drug's successful phase 3 cardiovascular outcomes study, w…
- States sue Trump administration to halt Medicaid work-requirement rolloutFour states filed a lawsuit in the U.S. District Court in Oregon challenging the Trump administration's Medicaid work-requirement changes. The complaint alleges the overhaul would cause sovereign,…